Cell MedX Corp.

Equities

CMXC

US15115X1072

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:55:18 2024-04-25 am EDT			5-day change	1st Jan Change
0.032 ^USD	-25.58%		-33.33%	+45.45%

Apr. 15	Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI
Mar. 12	Cell MedX Corp. announced that it has received $0.075 million in funding	CI

Cell MedX Corp. Reports Earnings Results for the Third Quarter Ended February 28, 2021

April 09, 2021 at 01:54 pm EDT

Cell MedX Corp. announced earnings results for the third quarter ended February 28, 2021. For the third quarter, the company announced sales was USD 4,374 compared to USD 2,380 a year ago. Net loss was USD 179,008 compared to USD 360,908 a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.01 a year ago. For the nine months, sales was USD 7,712 compared to USD 14,480 a year ago. Net loss was USD 569,546 compared to USD 909,683 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.

Latest news about Cell MedX Corp.

Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 15	CI
Cell MedX Corp. announced that it has received $0.075 million in funding	Mar. 11	CI
Cell Medx Corp. Announces Resignation of Brad Hargreaves from the Board of Directors	Feb. 27	CI
Cell MedX Corp. Appoints George Adams as Chairman of the Board	Feb. 25	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 16	CI
Cell MedX Corp. Announces Chief Executive Officer Changes	Dec. 19	CI
Cell MedX Corp. Announces Board Appointments	Dec. 19	CI
Cell MedX Corp. Announces Board Changes	Nov. 09	CI
Cell MedX Corp. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-16	CI
Cell MedX Corp. Reports Earnings Results for the Full Year Ended May 31, 2023	23-09-01	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	23-06-29	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	23-05-19	CI
Cell MedX Corp. Reports Earnings Results for the First Quarter Ended August 31, 2022	23-04-19	CI
Cell MedX Corp. Reports Earnings Results for the Full Year Ended May 31, 2022	23-04-07	CI
Cell MedX Corp. Auditor Raises 'Going Concern' Doubt	23-04-06	CI
Cell MedX Corp. Appoints Dwayne Yaretz as Chief Executive Officer Replacing Frank McEnulty	22-04-27	CI
Cell Medx Corp Appoints Dwayne Yaretz to the Board of Directors	22-04-27	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	22-04-11	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021	22-01-12	CI
Cell MedX Corp. Announces FDA Commences Review of Cell MedX's Premarket Notification and Health Canada Renews Class II Medical Device Licenses for Ebalance(R) Systems	21-11-15	CI
Cell Medx Corp. Reports Earnings Results for the First Quarter Ended August 31, 2021	21-10-14	CI
Cell MedX Corp. Files Premarket Notification with the US Food and Drug Administration	21-09-17	CI
Cell Medx Corp. Reports Earnings Results for the Full Year Ended May 31, 2021	21-08-30	CI
Cell MedX Corp. Auditor Raises 'Going Concern' Doubt	21-08-29	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter Ended February 28, 2021	21-04-09	CI

Chart Cell MedX Corp.

Duration

Period

More charts

Company Profile

Cell MedX Corp. is a biotechnology company. It is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, general health, pain relief, wellness and alleviate complications associated with medical conditions including, diabetes, Parkinsonâs disease, high blood pressure, neuropathy, and kidney function. The Company, through its subsidiary, is engaged in developing and manufacturing therapeutic devices based on its eBalance technology, which harnesses the power of microcurrents and its effects on the human body. The eBalance Pro System and eBalance Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities. Its Microcurrent therapy uses molecular bioelectricity in cell-to-cell signaling.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELL MEDX CORP.	+45.45%	9.51M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research